All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Bookmark this article
The Lupus Hub was pleased to speak to Murray Urowitz, University of Toronto, Toronto, CA. We asked, What do HCPs need to know about LN and the prevention of progression to end-stage renal disease (ESRD)?
What do HCPs need to know about LN and the prevention of progression to ESRD?
Urowitz begins by highlighting the incidence of ESRD in patients with lupus, with estimates ranging from 8% to 17% over 10 years. He then examines the factors associated with advancement to Grade 4 and 5 chronic kidney disease. He also presents data on the relationship between time to remission, number of flares in the first 5 years after initial remission, and the number of years a patient is on immunosuppressant therapy with the development of chronic kidney disease. Finally, he discusses how this data could inform lupus treatment and ultimately reduce the incidence of progression to ESRD.
Using the EULAR/ACR criteria to assess organ damage in patients with SLE and LN
Here, we evaluate EULAR/ACR criteria as a prognostic tool for patients with SLE and explore the relationship between lupus nephritis at diagnosis and organ damage after 3...
Editorial theme | Trajectories of depressive symptoms in SLE
Here, we discuss the impact of depression on quality of life in patients with SLE and the risk factors associated with depression from a paper by Chawla et al.
Subscribe to get the best content related to lupus delivered to your inbox